Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Dr Martens shares surge on turnaround hopes, outlook

(Sharecast News) - Shares in UK footwear company Dr Martens surged by more than 20% on Thursday as the firm said it expected 2026 earnings to be in line with guidance and would cut discounts in the Americas and EMEA regions under a turnaround plan led by new boss Ije Nwokorie. It added that prices would remain unchanged despite the impact of US tariffs as all of its spring/summer stock was in the market, and by the start of July most autumn/winter ranges would have arrived or be in transit.

More than 60% of Dr Martens shoes come from Vietnam, which faces a 46% "reciprocal" tariff from July under US President Donald Trump's attack on global trade partners.

"We generate strong product gross margins, which is helpful given that tariffs are charged on cost, not retail price," the company, which has issued a raft of profit warnings over the past year, said.

"We do however recognise that there is continued macroeconomic uncertainty and the full outcome of tariffs is still unknown, and we will monitor this closely through the year and take action as appropriate."

Adjusted pre-tax profit fell to £34.1m from £97.2m, beating analysts' consensus of £30.6m, according to a company-compiled poll. The company is guiding for earnings of £54m to £74m for fiscal 2026.

"We will reduce discounting in Americas and EMEA, across both our own ecommerce channel and through wholesale, with the aim of driving full price sales. We have a positive autumn/winter wholesale order book in EMEA and the USA order book is currently broadly in line with last year, before the benefit of any in-season re-orders," the iconic bootmaker said.

Pre-tax profit for the year to March fell to £8.8m from £93m as revenue dived 10% to £787.6m against a challenging macroeconomic and consumer backdrop in several of the company's core markets.

Nwokorie said direct to consumer sales in its key US market had bounced back to growth in the second half of the year, while net debt fell £110.3m to £249.5m, ahead of guidance of £310m to £330m.

However, it added that UK revenues have remained lower since the year-end "due to a challenging market", while unfavourable foreign exchange rates would see it take a hit to group sales and profits of around £18 m and £3m respectively in 2025-26.

It also expected inventory to be broadly flat year-on-year and plans to open 20 to 25 new stores.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.